Phase I study of the novel distamycin derivative tallimustine (FCE 24517)
Authors:
- 1 December 1994
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 5 (10) , 901-907
Abstract
Tallimustine, a benzoyl nitrogen mustard derivative of the antiviral agent distamycin A, is a new alkylat-ing agent which binds to A-T rich regions of DNA in the minor groove producing highly sequence-specific alkylations. Its main preclinical features are a significant antitumour activity in animal models and a lack of cross-resistance in vitro and in vivo with L-PAM. Myelotoxicity was dose-limiting in animals, with a more than 100-fold difference in bone marrow sensitivity between mice and dogs. Forty adult patients (pts) with solid malignancies were entered in the study. The drug was administered as an IV bolus every 4 weeks. CBC was repeated twice a week and serial assessments of renal function were performed in the week following the first cycle. From the starting dose of 50 μg/m2, corresponding to 1/3 of the highest non-toxic dose (HNTD) in dogs, there were increases through 10 dose levels, with reliance only on the features of the myelotoxicity observed. The main toxic effect was neutropenia which was dose-limiting, selective and short-lasting. Only previously-untreated pts received doses of 750 μg/m2 or more, withgrade 4 neutropenia occurring in ≥75% of the cycles. The maximally tolerable dose (MTD) was defined as 1250 μg/m2, with 3 of 3 pts developing febrile neutropenia requiring IV antibiotics. A platelet count of < 100 × 103/μl was observed in only one pt. Bone marrow aspiration performed in selected pts on days 8 and 15 confirmed a highly selective impairment by tallimustine of the myeloid lineage, with rapid recovery of the proliferative compartment. Pharmacokinetic studies performed at 1000 μg/m2 and 1250 μg/m2 showed a rapid fall of the plasma levels within the first 2 hours with drug concentrations between 100 ng/ml and 400 ng/ml within the first hour. A partial response of 4 months' duration was reported in one previously-untreated pt with cutaneous recurrences of malignant mesothelioma. The report of some antitumour efficacy, the high selectivity of neutropenia, the lack of significant non-hematological toxic effects and the occurrence of detectable but still low plasma drug concentrations suggest that further clinical evaluation of higher doses of tallimustine in combination with colony-stimulating factors would be justified.Keywords
This publication has 11 references indexed in Scilit:
- Establishment of l1210 leukemia cells resistant to the distamycin‐a derivative (FCE 24517): Characterization and cross‐resistance studiesInternational Journal of Cancer, 1993
- Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.Journal of Clinical Oncology, 1992
- Comparativein vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cellsInvestigational New Drugs, 1992
- Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin ABritish Journal of Cancer, 1991
- Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1990
- Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivativesJournal of Medicinal Chemistry, 1989
- Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancerCancer Chemotherapy and Pharmacology, 1989
- High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancerCancer Chemotherapy and Pharmacology, 1987
- High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinomaCancer Chemotherapy and Pharmacology, 1985
- Reporting results of cancer treatmentCancer, 1981